Irbesartan + Hidroclorotiazida Pharmakern

Irbesartan, the active ingredient in Irbesartan + Hydrochlorothiazide Pharmakern, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It helps control high blood pressure in adult patients.

GNH USA supplies Irbesartan + Hydrochlorothiazide Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used in the management of cardiovascular conditions related to elevated blood pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure. - Secondary hypertension due to renal disease: improves blood pressure control. - High‑risk cardiovascular patients with hypertension: reduces the risk of stroke and myocardial infarction.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urination or mild dehydration. - Electrolyte disturbances such as low potassium.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance requiring medical attention. - Angioedema or severe allergic reaction. - Acute kidney injury or significant rise in serum creatinine. - Hepatic dysfunction or jaundice. - Life‑threatening hypotension.

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Electrolyte assessment: monitor potassium and sodium levels, especially with diuretic use. - Renal function: evaluate baseline creatinine and glomerular filtration rate. - Pregnancy: avoid unless benefits outweigh potential risks; discuss with a healthcare professional. - Drug interactions: review concomitant medications for additive effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - Lithium: increased lithium toxicity. - ACE inhibitors or other ARBs: additive hypotension and renal impairment. - NSAIDs: may blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood pressure lowering. - CYP2C9 substrates (e.g., warfarin): possible alteration of metabolism. - Antidiabetic agents: may require dose adjustment due to changes in glucose control.